This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Regeneron (REGN) Announces Positive Data on Oncology Candidate
by Zacks Equity Research
Regeneron's (REGN) REGN7075, in combination with its oncology drug Libtayo, generates anti-tumor responses in patients with microsatellite-stable colorectal cancer.
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
by Zacks Equity Research
The FDA assigns a new target action date of Dec 29, 2024, to Bristol Myers (BMY) BLA for subcutaneous nivolumab (nivolumab and hyaluronidase).
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
Wall Street Analysts Think ALX Oncology Holdings (ALXO) Could Surge 36.64%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ALX Oncology Holdings (ALXO) points to a 36.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
by Zacks Equity Research
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna
by Zacks Equity Research
Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.
Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More
by Zacks Equity Research
Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.
ALX Oncology (ALXO) Up 56% on Upbeat Gastric Cancer Study Data
by Zacks Equity Research
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ALX Oncology Holdings Inc. (ALXO) Loses -18.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for ALX Oncology Holdings Inc. (ALXO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales
by Zacks Equity Research
Merck (MRK) beats on Q2 estimates for earnings and sales. The company continues to see robust growth in COVID drug sales and Keytruda and Gardasil sales.
Alkermes' (ALKS) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Alkermes (ALKS) beat estimates for both earnings and sales in the second quarter of 2022. The company narrows sales guidance for Vivitrol and Aristada. Stock down.
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
by Zacks Equity Research
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
New Strong Sell Stocks for January 19th
by Zacks Equity Research
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Earnings Season Could Be Great for ALX Oncology (ALXO)
by Zacks Equity Research
ALX Oncology (ALXO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.